

Inhibition of HIF-1 α through Suppression of NF- κ B Activation by Compounds Isolated from *Senecio graveolens*



Authors

Luis Apaza Ticona^{1, 2} , Nuria Cano-Adamuz¹, Andreea Madalina Serban³, Ángel Rumbero Sánchez¹

Affiliations

- 1 Department of Organic Chemistry, Faculty of Sciences, University Autónoma of Madrid, Cantoblanco, Madrid, Spain
- 2 Department of Pharmacology, Pharmacognosy and Botany, Faculty of Pharmacy, University Complutense of Madrid, Madrid, Spain
- 3 Maria Sklodowska Curie University Hospital for Children, Bucharest, Romania

Key words

coumarins, sesquiterpene lactones, *Senecio graveolens*, Asteraceae, NF- κ B, HIF-1 α

received 17.06.2019

revised 16.11.2019

accepted 18.11.2019

Bibliography

DOI <https://doi.org/10.1055/a-1063-6722>

Planta Med Int Open 2020; 7: e1–e11

© Georg Thieme Verlag KG Stuttgart · New York

ISSN 2509-9264

Correspondence

Prof. Dr. Luis Apaza Ticona

Department of Organic Chemistry

Faculty of Sciences

University Autónoma of Madrid

Francisco Tomás y Valiente Street, 7


Cantoblanco

28049 Madrid

Spain

Tel.: +34 91 497 7622, Fax: +34 91 497 4715

luis.apaza@uam.es; lnapaza@ucm.es

 **Supporting Information** for this article is available online at <http://www.thieme-connect.de/products>

ABSTRACT

One of the characteristics of cancer is that the lack of oxygen in the cancer cells triggers changes in their gene expression. This hypoxia activates hypoxia-inducible factor 1-alpha and this in turn sets in motion the whole family of important angio-

genic genes for the tumour. Hypoxia-inducible factor 1-alpha therefore increases the density and vascular permeability within the tumours, facilitating their rapid growth and, later, the metastasis. *Senecio graveolens* is a South American medicinal plant commonly used for mountain sickness (lack of adaptation of the organism to hypoxia). Additionally, pharmacological studies showed that its alcoholic extracts have cytotoxic properties. This research aimed to perform a guided phytochemical study of *S. graveolens* to identify compounds capable of inhibiting hypoxia-inducible factor 1-alpha through suppression of nuclear factor kappa-light-chain-enhancer of activated B cell activation. The isolation led to the characterisation of phanurane (1), damsine (2), and scoparone (3), first reported in the *S. graveolens* species. Phanurane (1) showed inhibitory activity of hypoxia-inducible factor 1-alpha on the cancer cell lines U-373 MG (IC₅₀ = 20.66 ± 0.04 μM), A549 (IC₅₀ = 25.80 ± 0.04 μM), Hep G2 (IC₅₀ = 29.21 ± 0.03 μM), and Caco-2 (IC₅₀ = 38.58 ± 0.02 μM). Damsine (2) hypoxia-inducible factor 1-alpha displayed inhibitory activity of hypoxia-inducible factor 1-alpha on the cancer cell lines U-373 MG (IC₅₀ = 2.29 ± 0.07 μM), A549 (IC₅₀ = 4.13 ± 0.04 μM), Hep G2 (IC₅₀ = 6.40 ± 0.03 μM), and Caco-2 (IC₅₀ = 9.80 ± 0.04 μM). Finally, scoparone (3) displayed inhibitory activity of hypoxia-inducible factor 1-alpha on the cancer cell lines U-373 MG (IC₅₀ = 15.22 ± 0.01 μM), A549 (IC₅₀ = 17.47 ± 0.02 μM), Hep G2 (IC₅₀ = 18.26 ± 0.06 μM), and Caco-2 (IC₅₀ = 19.75 ± 0.04 μM). In addition, phanurane (1) displayed inhibitory activity over nuclear factor kappa-light-chain-enhancer of activated B cells on cancer cell lines U-373 MG (IC₅₀ = 7.13 ± 0.03 μM), A549 (IC₅₀ = 8.64 ± 0.03 μM), Hep G2 (IC₅₀ = 8.87 ± 0.04 μM), and Caco-2 (IC₅₀ = 15.11 ± 0.01 μM). Likewise, damsine (2) showed inhibitory activity over nuclear factor kappa-light-chain-enhancer of activated B cells on cancer cell lines U-373 MG (IC₅₀ = 2.28 ± 0.01 μM), A549 (IC₅₀ = 3.79 ± 0.02 μM), Hep G2 (IC₅₀ = 3.98 ± 0.05 μM), and Caco-2 (IC₅₀ = 6.41 ± 0.02 μM). Lastly, scoparone (3) displayed inhibitory activity of nuclear factor kappa-light-chain-enhancer of activated B cells on cancer cell lines U-373 MG (IC₅₀ = 3.62 ± 0.06 μM), A549 (IC₅₀ = 4.48 ± 0.03 μM), Hep G2 (IC₅₀ = 5.25 ± 0.01 μM), and Caco-2 (IC₅₀ = 11.90 ± 0.02 μM). This study corroborates the cytotoxic activity of the isolated compounds through the inhibition of hypoxia-inducible factor 1-alpha as well as its modulator nuclear factor kappa-light-chain-enhancer of activated B cells.

ABBREVIATIONS

ANGPT1	angiopoietin 1
BIRC5	baculoviral inhibitor of apoptosis repeat-containing 5
CA9	carbonic anhydrase IX
EPO	erythropoietin
GAPDH	glyceraldehyde 3-phosphate dehydrogenase
GLUT-1	glucose transporter 1
HIF-1 α	hypoxia-inducible factor 1-alpha
ILs	interleukins
LDHA	lactate dehydrogenase A
LOX	lysyl oxidase
MMP2	matrix metalloproteinase-2
MMP9	matrix metalloproteinase-9
NF- κ B	nuclear factor kappa-light-chain-enhancer of activated B cells
PDK1	pyruvate dehydrogenase lipoamide kinase isozyme 1
PGK1	phosphoglycerate kinase 1
PKM2	pyruvate kinase isozymes M2
pVHL	von Hippel-Lindau protein
RelA	transcription factor p65
SDF1	stromal cell-derived factor 1
VEGF	vascular endothelial growth factor

Introduction

Senecio graveolens Wedd. (synonym: *Senecio nutans* Sch. Bip) belongs to the family Asteraceae. *S. graveolens*, also known as “Chachakuma”, is a perennial shrub about 20–60 cm high that grows in habitats with heights fluctuating between 3500–5000 metres above sea level in the Andes Chile, Argentina, Peru, and Bolivia. It is a medicinal plant widely used by the communities living in these areas in the form of an infusion and decoction. The infusion of leaves and stems is used to ameliorate altitude sickness (principally as vasodilator preparations), headaches, stomach pain, intestinal inflammations, colitis, nausea, fever, pulmonary diseases, and bronchitis [1–4]. The decoction of leaves, stems, and roots is used against all types of pulmonary affections such as a brain tonic and against nervousness and excessive sweating [1, 3–5]. Pharmacological studies have shown that the ethanolic extract of *S. graveolens* possesses cytotoxic activity in MCF-7 cancer cells at a concentration of 200 μ g/mL [6].

Human cancers frequently contain areas of necrosis in which cancer cells have died due to inadequate oxygenation [7, 8]. Cells closest to a perfused blood vessel are exposed to relatively high O₂ concentrations, which decline as distance from the vessel increases. Although such gradients exist in normal tissues, in cancers, the gradients are much steeper and O₂ concentrations drop to near zero in areas of necrosis. In addition to physical gradients, temporal fluctuations in oxygenation also commonly occur within tumours [9]. This activates HIF-1 α , which in turn sets in motion the whole family of important genes that collaborate with different aspects essential for tumourigenesis and tumour progression, i. e.,

genes associated with angiogenesis (VEGF, SDF1, ANGPT1), survival (BIRC5, EPO), reprogramming from an oxidative metabolism to a glycolytic metabolism (GLUT-1, LDHA, PDK1, GAPDH, PGK1, PKM2), and epithelial-mesenchymal transition and metastasis (LOX, MMP2, MMP9) [10, 11].

HIF-1 α therefore increases the density and vascular permeability within the tumours facilitating their growth and later the feared metastasis, since the vessels are the outlet for cancer cells capable of colonising other tissues [12, 13]. Regardless of hypoxia, in some tumours, such as hemangioblastomas and renal carcinomas, the activation of HIF-1 α is related to the functional inactivation of the suppressor gene for pVHL, which decreases degradation and increases the total HIF-1 α of the cell, even in normoxia [14, 15].

Under hypoxic conditions, phosphorylation of κ B and the subsequent activation of the NF- κ B subunits p50 and p65 (RelA) has been reported to contribute to basal levels of HIF-1 α mRNA and protein, and to mediate HIF-1 α expression and promoter activity in response to thrombin, H₂O₂, and even short-term hypoxia. Indeed, the NF- κ B subunits p50 and p65 have been shown to directly interact with HIF-1 α at an NF- κ B consensus site in the HIF-1 α promoter at -197/-188 bp under these conditions. In addition to the stabilisation of HIF-1 α under hypoxia conditions, van Uden et al. [16] described how the NF- κ B complex is a direct modulator of HIF-1 α expression in a manner dependent on stimulation with TNF- α in normoxic conditions [17–19].

The aim of the present research was to perform a bioguided phytochemical study to identify compounds of *S. graveolens* with the capacity to inhibit HIF-1 α through suppression of NF- κ B activation as future antitumour compounds.

Results


Previously isolated compounds of the *S. graveolens* species belong to a range of structural groups such as monoterpenoids, germacrenes, eremophilanes, sesquiterpenes, *p*-hydroxyacetophenone derivatives and shikimic acid derivatives, benzofurans, and benzopyrans, which show a structural relationship with the previously unreported compounds isolated in this work [20–22]. Their structures were elucidated through ¹H and ¹³C NMR, 2D spectroscopic, and HR-ESIMS analyses. Based on the reported data, they were identified as spironolactone (phanurane), sesquiterpene lactone (damsine), and coumarin (scoparone) (► **Fig. 1**), isolated for the first time from this plant species.

U-373 MG (human glioblastoma astrocytoma), A549 (human Caucasian lung carcinoma), Hep G2 (human Caucasian hepatocyte carcinoma), and Caco-2 (human Caucasian colon adenocarcinoma) cancer cell lines were selected to carry out the *in vitro* cytotoxicity and activity assays of the *S. graveolens* extracts and compounds. We selected these cancer cell lines according to their physiological relationship with certain diseases that are treated with *S. graveolens* in traditional medicine [1–4]. Therefore, the relationship is for mountain sickness, characterised by symptoms such as headache (U-373 MG cell line), respiratory diseases (A549 cell line), stomach pain, and colitis (Hep G2 and Caco-2 cell lines). In addition, a non-cancerous cell line (PMBC) was used to assess the safety of the compounds.

After examining the cytotoxicity of the *S. graveolens* extracts in hypoxic conditions (1% O₂) after 72 h of treatment (► **Table 1**), we observed that all of them had a greater cytotoxic effect on the cancer cell line U-373 MG, which is a human glioblastoma astrocytoma cell line. We also observed that the dichloromethane/methanol extract was more active than the aqueous extract and the *n*-heptanic extract. These results corroborate those shown by Echiburú-Chau et al. [6], who by means of the neutral red uptake test observed that at a concentration of 200 µg/mL ethanolic extract of *S. graveolens* exhibited cytotoxicity in breast cancer cell lines ZR-75-1, MCF-7, and MDA-MB-231 at 24 h of treatment under hypoxic conditions, without damaging the MCF-10F cell line. However, at this concentration, the ethanolic extract of *S. graveolens* showed a greater cytotoxic effect on the cell line MDA-MB-231 (50%) com-

pared to the other cancer lines ZR-75-1 (9%) and MCF-7 (6%) [6]. Finally, both MTT and LDH assays showed that dichloromethane/methanol and aqueous extracts have cytotoxic effects higher than 100 µg/mL in the PBMCs. On the contrary, the *n*-heptanic extract was discarded due to its cytotoxic effect in PBMCs with a CC₅₀ of 99.62 ± 2.22 µg/mL and 91.02 ± 3.60 µg/mL measured by the MTT and LDH assays, respectively.

Afterwards, we evaluated the dichloromethane/methanol and the aqueous extracts inhibitory activity over NF-κB (► **Table 2**) and HIF-1α (► **Table 3**) on the same cell lines under equal conditions. The dichloromethane/methanol extract presented a higher inhibitory effect on both transcription factors in all cell lines. Again, the lower IC₅₀ values were those shown on the brain cancer cell line



► **Fig. 1** Chemical structures Phanurane (1), Damsine (2) and Scoparone (3).

► **Table 1** MTT and LDH cytotoxicity assays of *S. graveolens* extracts against a panel of human cancer cell lines and one noncancerous cell line after 72 h of treatment under hypoxic (1% O₂) conditions. The results are the means (±SD) of three separate experiments performed in triplicate. Control = untreated cells.

Samples	CC ₅₀ (µg/mL)				
	PBMCs	U-373 MG	A549	Hep G2	Caco-2
Control (untreated cells)	100.01 ± 3.45	100.00 ± 1.23	99.95 ± 1.87	99.98 ± 2.67	100.10 ± 2.21
Heptanic extract ^(a)	99.62 ± 2.22	41.74 ± 1.62	57.15 ± 2.42	78.66 ± 2.67	98.79 ± 4.62
Dichloromethane/methanol extract ^(a)	> 100 ± 1.64	31.40 ± 2.32	46.52 ± 2.26	68.97 ± 3.66	98.05 ± 3.67
Aqueous extract ^(a)	> 100 ± 1.75	33.48 ± 4.81	47.84 ± 2.67	74.73 ± 2.69	98.46 ± 1.65
Control (untreated cells)	99.96 ± 3.45	99.90 ± 2.65	100.11 ± 3.11	99.92 ± 2.87	100.09 ± 2.74
Heptanic extract ^(b)	91.02 ± 3.60	40.08 ± 1.46	54.24 ± 4.36	76.21 ± 3.50	95.71 ± 2.67
Dichloromethane/methanol extract ^(b)	> 100 ± 1.09	31.38 ± 1.95	42.02 ± 1.71	66.18 ± 2.05	94.93 ± 1.85
Aqueous extract ^(b)	> 100 ± 1.56	31.94 ± 2.09	47.12 ± 2.40	74.50 ± 1.37	95.63 ± 3.48

^(a) Cytotoxicity values of the MTT assay; ^(b) Cytotoxicity values of the LDH assay

► **Table 2** Inhibitory effect of *S. graveolens* extracts on NF-κB activation in a panel of human cancer cell lines and one noncancerous cell line after 72 h of treatment under hypoxic (1% O₂) conditions. The results are the means (±SD) of three separate experiments performed in triplicate. Control = untreated cells.

Samples	CC ₅₀ (µg/mL)				
	PBMCs	U-373 MG	A549	Hep G2	Caco-2
Control	11.98 ± 0.01	12.43 ± 0.01	12.23 ± 0.08	12.45 ± 0.09	12.65 ± 0.08
DMSO	5.96 ± 0.05	6.35 ± 0.02	6.45 ± 0.03	6.23 ± 0.07	6.62 ± 0.08
Dichloromethane/methanol extract	3.89 ± 0.01	4.40 ± 0.02	5.35 ± 0.01	9.58 ± 0.04	10.44 ± 0.01
Aqueous extract	14.56 ± 0.02	20.29 ± 0.05	27.24 ± 0.02	30.23 ± 0.04	39.89 ± 0.03
JSH-23	7.09 ± 0.01 µM	6.99 ± 0.02 µM	7.10 ± 0.02 µM	7.10 ± 0.03 µM	7.11 ± 0.01 µM

U-373 MG in comparison with the rest of the cancerous cell lines. Nevertheless, the inhibitory effect was even higher on the PBMCs.

For the fractionation and isolation of the compounds of *S. graveolens*, the dichloromethane/methanol extract was selected because it showed no cytotoxic effect on the PBMCs, besides showing greater inhibitory activity over NF- κ B and HIF-1 α with respect to the aqueous extract.

Regarding the compounds (phanurane, damsine, and scoparone) isolated from the dichloromethane/methanol extract of *S. graveolens*, they were individually more cytotoxic than the crude extract in the same hypoxic conditions (1% O₂) at 72 h of treatment. U-373 MG cell line viability remained as the most affected one by the three compounds with respect to the cancer cell lines A549, Hep G2, and Caco-2 (► **Table 4**). Besides, the isolated compounds did not show a cytotoxicity higher than 100 μ M on the noncancerous cell line (PBMCs) by the MTT assay. However, in the LDH assay, phanurane, damsine, and scoparone compounds showed CC₅₀s of 90.11 \pm 0.99, 79.62 \pm 2.23, and 89.79 \pm 1.12 μ M on the PBMCs.

Phanurane (**1**) showed a cytotoxic effect by means of the MTT assay under hypoxic conditions (1% O₂) on the cancer cell lines U-373 MG, A549, Hep G2, and Caco-2 with CC₅₀s of 23.63 \pm 1.47, 28.54 \pm 2.25, 45.33 \pm 1.09, and 68.49 \pm 3.50 μ M at 72 h of treatment. However, using the LDH assay under hypoxic conditions (1% O₂) at 72 h of treatment, phanurane showed CC₅₀s of 21.30 \pm 1.09, 27.44 \pm 3.18, 44.47 \pm 1.77, and 67.89 \pm 1.38 μ M on the cancer lines mentioned above. There are no reports of phanurane cytotoxicity assays on cell lines.

Damsine (**2**) showed a cytotoxic effect by means of the MTT and LDH assays under hypoxic conditions (1% O₂) at 72 h of treatment on the cancer cell lines U-373 MG, A549, Hep G2, and Caco-2 with

CC₅₀s of 12.40 \pm 2.28, 23.80 \pm 1.06, 39.07 \pm 2.43, 63.79 \pm 1.48 μ M and 12.25 \pm 1.10, 21.91 \pm 2.66, 35.09 \pm 3.05, 60.76 \pm 1.12 μ M, respectively. Our results corroborate the cytotoxic activity of damsine described by Saeed et al. [23], who observed cytotoxic activity (as measured by the resazurin reduction assay) at 24 h of damsine treatment on brain and colon cancer cell lines U87 MG/U87 Δ EGFR and HCT116. P53^{+/+}/HCT116 P53^{-/-} with CC₅₀s of 154.4 \pm 8.9/24.1 \pm 1.5 μ M and 32.5 \pm 6/133.6 \pm 18.4 μ M, respectively. In addition, there are reports that damsine has cytotoxic activity at 72 h of treatment on breast cancer cell lines MCF-7, JIMT-1, and HCC1937 with CC₅₀s of 3.7 \pm 0.4, 3.3 \pm 0.6, and 6.8 \pm 0.4 μ M, respectively [24].

Scoparone (**3**) showed a cytotoxic effect under hypoxic conditions (1% O₂) with CC₅₀s of 18.47 \pm 1.49, 24.67 \pm 1.34, 41.92 \pm 2.39, and 66.39 \pm 2.75 μ M by means of the MTT assay and 16.84 \pm 2.80, 23.82 \pm 2.40, 41.59 \pm 2.66, and 64.42 \pm 1.76 μ M by means of the LDH assay on the cancer cell lines U-373 MG, A549, Hep G2, and Caco-2 after 72 h of treatment. There are also reports that scoparone significantly inhibited the proliferation of DU145 cells, with a CC₅₀ value of 41.3 μ M after 72 h of treatment [25].

Concerning the inhibition of NF- κ B production in hypoxic conditions (1% O₂), the isolated compounds of the dichloromethane/methanol extract of *S. graveolens* were compared with respect to the positive control JSH-23 (IC₅₀ = 7.1 μ M) [26]. Phanurane, damsine, and scoparone compounds showed a greater effect on the brain cancer cell line with respect to the lung, liver, and colon cancer cell lines after 72 h of treatment (► **Fig. 2**).

Phanurane (**1**) inhibited the production of NF- κ B under hypoxic (1% O₂) conditions on the cancer cell lines U-373 MG, A549, Hep G2, and Caco-2 with IC₅₀s of 7.13 \pm 0.03, 8.64 \pm 0.03, 8.87 \pm 0.04,

► **Table 3** Inhibitory effect of *S. graveolens* extracts on HIF-1 α in a panel of human cancer cell lines and one noncancerous cell line after 72 h of treatment under hypoxic (1% O₂) conditions. Control = untreated cells.

Samples	CC ₅₀ (μ g/mL)				
	PBMCs	U-373 MG	A549	Hep G2	Caco-2
Control	90.97 \pm 0.02	96.71 \pm 0.05	98.84 \pm 0.05	97.82 \pm 0.06	99.97 \pm 0.03
Dichloromethane/methanol extract	6.26 \pm 0.09	9.39 \pm 0.03	15.72 \pm 0.06	19.63 \pm 0.05	32.51 \pm 0.07
Aqueous extract	20.25 \pm 0.09	25.87 \pm 0.08	30.22 \pm 0.07	41.89 \pm 0.02	84.89 \pm 0.05
2-MeOE2	0.49 \pm 0.02 μ M	0.48 \pm 0.01 μ M	0.50 \pm 0.01 μ M	0.49 \pm 0.02 μ M	0.51 \pm 0.02 μ M

► **Table 4** MTT and LDH cytotoxicity assays of *S. graveolens* compounds against a panel of human cancer cell lines and one noncancerous cell line after 72 h of treatment under hypoxic (1% O₂) conditions. Control = untreated cells.

Samples	CC ₅₀ (μ g/mL)				
	PBMCs	U-373 MG	A549	Hep G2	Caco-2
Control (untreated cells)	99.98 \pm 2.12	99.97 \pm 3.43	100.01 \pm 2.16	100.18 \pm 3.07	99.90 \pm 3.11
Compound 1 ^(a)	> 100 \pm 2.51	23.63 \pm 1.47	28.54 \pm 2.25	45.33 \pm 1.09	68.49 \pm 3.50
Compound 2 ^(a)	> 100 \pm 3.28	12.40 \pm 2.28	23.80 \pm 1.06	39.07 \pm 2.43	63.79 \pm 1.48
Compound 3 ^(a)	> 100 \pm 1.25	18.47 \pm 1.49	24.67 \pm 1.34	41.92 \pm 2.39	66.39 \pm 2.75
Control (untreated cells)	100.03 \pm 2.11	100.97 \pm 3.11	100.91 \pm 2.91	100.95 \pm 3.43	99.91 \pm 3.56
Compound 1 ^(b)	90.11 \pm 0.99	21.30 \pm 1.09	27.44 \pm 3.18	44.47 \pm 1.77	67.89 \pm 1.38
Compound 2 ^(b)	79.62 \pm 2.23	12.25 \pm 1.10	21.91 \pm 2.66	35.09 \pm 3.05	60.76 \pm 1.12
Compound 3 ^(b)	89.79 \pm 1.12	16.84 \pm 2.80	23.82 \pm 2.40	41.59 \pm 2.66	64.42 \pm 1.76

^(a)Cytotoxicity values of the MTT assay; ^(b)Cytotoxicity values of the LDH assay.

and $15.11 \pm 0.01 \mu\text{M}$ at 72 h of treatment. There are no reports that phanurane has inhibited the production of NF- κB in cancer cell lines.

Damsine (**2**) inhibited the production of NF- κB under hypoxic (1% O_2) conditions at 72 h of treatment with IC_{50} s of 2.28 ± 0.01 , 3.79 ± 0.02 , 3.98 ± 0.05 , and $6.41 \pm 0.02 \mu\text{M}$ on cancer cells U-373 MG, A549, Hep G2, and Caco-2, respectively. Also, there are reports that damsine inhibited the expression of NF- κB on cancer cell line Caco-2 with an IC_{50} of $7.2 \mu\text{M}$ after 6 h of treatment [27].

Scoparone (**3**) inhibited the production of NF- κB under hypoxic (1% O_2) conditions at 72 h of treatment on the cancer cell lines U-373 MG, A549, Hep G2, and Caco-2 with IC_{50} s of 3.62 ± 0.06 , 4.48 ± 0.03 , 5.25 ± 0.01 , and $11.90 \pm 0.02 \mu\text{M}$, respectively. Scoparone has also been reported to inhibit the expression of NF- κB on cancer cell line U-937 with an IC_{50} of 10 nM after 24 h of treatment [28].

Finally, under hypoxic conditions, the isolated compounds of the dichloromethane/methanol extract of *S. graveolens* were compared with respect to the positive control 2-MeOE2 ($\text{IC}_{50} = 0.5 \mu\text{M}$)


[29]. Phanurane, damsine, and scoparone compounds showed an inhibitory effect on HIF-1 α on the cancer cell lines U-373 MG, A549, Hep G2, and Caco-2 at 72 h of treatment (► **Fig. 3**).

Phanurane (**1**) inhibited HIF-1 α under hypoxic (1% O_2) conditions at 72 h of treatment with IC_{50} s of 20.66 ± 0.04 , 25.80 ± 0.04 , 29.21 ± 0.03 , and $38.58 \pm 0.02 \mu\text{M}$ on cancer cells U-373 MG, A549, Hep G2, and Caco-2, respectively.


Damsine (**2**), under hypoxic (1% O_2) conditions at 72 h of treatment on the cancer cell lines U-373 MG, A549, Hep G2, and Caco-2, inhibited HIF-1 α with IC_{50} s of 2.29 ± 0.07 , 4.13 ± 0.04 , 6.40 ± 0.03 , and $9.80 \pm 0.04 \mu\text{M}$, respectively.

Scoparone (**3**) inhibited HIF-1 α under hypoxic (1% O_2) conditions on the cancer cell lines U-373 MG, A549, Hep G2, and Caco-2 with IC_{50} s of 15.22 ± 0.01 , 17.47 ± 0.02 , 18.26 ± 0.06 , and $19.75 \pm 0.04 \mu\text{M}$, respectively, at 72 h of treatment.

There are no reports on the inhibition of HIF-1 α by means of the phanurane, damsine, and scoparone compounds.



► **Fig. 2** Inhibitory effect of *S. graveolens* compounds on NF- κB activation in a panel of human cancer cell lines and one noncancer cell line after 72 h of treatment under hypoxic (1% O_2) conditions. Control = untreated cells.



► **Fig. 3** Inhibitory effect of *S. graveolens* compounds on HIF-1 α in a panel of human cancer cell lines and one noncancer cell line after 72 h of treatment under hypoxic (1% O₂) conditions. Control = untreated cells.

Discussion

There is an extensive phytochemical analysis on the essential oil (46 compounds) of *S. graveolens*, where monoterpene hydrocarbons predominate, with sabinene and α -terpinene as the main components [30, 31]. The main activity of the essential oil of *S. graveolens* is antimicrobial [32, 33]. On the other hand, only 14 compounds present in the hydroalcoholic extract have been identified from the aerial parts of *S. graveolens*. The compounds dihydroeuparin, 4-hydroxy-3-(isopenten-2-yl) acetophenone, 3-hydroxy-2,2-dimethyl-6-acetylchromane, 5-acetylsalicylaldehyde, 4-hydroxy-3-(3'-hydroxyisopentyl) acetophenone, scopoletin, 3-phenyl-4-hydroxyacetophenone, 4-hydroxyacetophenone, 4-hydroxy-3-methoxyacetophenone, 4-hydroxy-3-(3-methyl-2-butenyl) acetophenone, 5-acetyl-6-hydroxy-2-isopropenyl-2,3-dihydrobenzofurane, 4-acetylphenyl- α -D-glucopyranoside, 1-(3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-chromen-6-yl) ethanone, and

1-(2,2-dimethyl-3,4-dihydro-2H-chromen-6-yl) ethanone are polyphenolic in nature [20–22, 34]. There are few works on the pharmacological activities of *S. graveolens*. With respect to the hydroalcoholic extract of *S. graveolens*, only antimicrobial, antioxidant, vasodilator, hypotensive, and antihypertensive activities have been tested. [34–37].

Regarding the cytotoxicity of *S. graveolens*, Echiburú-Chau et al. [6] reported that the alcoholic extract could induce cytotoxicity under hypoxic conditions in different breast cancer cell lines (ZR-75-1, MCF-7, and MDA-MB-231), but not in non-tumorigenic cells (MCF-10F). However, compound 4-hydroxy-3-(3-methyl-2-butenyl) acetophenone, mostly present in the alcoholic extract, did not show effective anticancer activity compared to the complete extract. The mechanisms responsible for the cytotoxicity exerted by the alcoholic extract of *S. graveolens* are not clear. It is very likely that the relative contribution of apoptosis and autophagy to the

cytotoxic effects of *S. graveolens* depends mainly on the genetic profile of the analysed cells, since alterations in the known oncogenic pathways (for example, P53) modify the way in which a cell responds to external stimuli.

Our study revealed that the dichloromethane/methanol extract of *S. graveolens* showed a greater inhibitory activity on NF- κ B and HIF-1 α than the aqueous extract of *S. graveolens* in all tumour cell lines (U-373 MG, A549, Hep G2, Caco-2) tested. Besides, both extracts did not show cytotoxicity over PBMCs non-tumourous cell line. We also observed that the *n*-heptanic extract of *S. graveolens* presented cytotoxicity over PBMCs non-tumourous cell line, and its activity over NF- κ B and HIF-1 α was lower with respect to the dichloromethane/methanol and aqueous extracts. For that reason, we selected the dichloromethane/methanol extract for subsequent fractionation. The dichloromethane/methanol extract was separated by bioguided analysis, determining the activity of each fraction over NF- κ B and HIF-1 α (data not shown).

The interest in the role of HIF-1 in cancer biology has grown exponentially because the usual conditions within most solid tumour masses occur are anoxia (absence of oxygen) or hypoxia (low oxygen concentrations). These situations activate HIF-1 protein, which consists of two subunits, α 1 (inducible), and β 1 (constitutively expressed). Under normoxia conditions (normal oxygen concentrations), the α 1 subunit is very labile, and degrades at the same rate at which it is synthesised [38]. However, under hypoxia conditions, this subunit is stabilised and dimerizes with the β 1 subunit. This heterodimer migrates to the nucleus, where it binds to specific DNA sequences, activating genes involved in adaptation to hypoxia, cell survival, angiogenesis, and metastasis, such as, for example, VEGF, TGF- α , GLUT-1, or CA9, among many others, which we know are involved in tumour development and aggressiveness [39–41]. Also, HIF-1 α has been shown to be regulated by cytokines such as ILs, TNF- α , and NF- κ B [42].

NF- κ B is a central molecule that regulates the expression of various target genes that promote cell proliferation, modulate immune responses, and play a role in the pathogenesis of various diseases, including cancer [43, 44]. When analysing the possible mechanism by NF- κ B inhibition of the compounds isolated from the dichloromethane/methanol extract of *S. graveolens*, we could indicate that damsine acts on sulfhydryl groups of cysteine residues in the DNA-binding domain of the NF- κ B subunit through its exomethylene group [45]. Likewise, the unsaturated carbonyl group and the methylene-lactone ring present in damsine can exert a direct alkylation effect on the p65 subunit of NF- κ B without inhibiting the degradation of I κ B [46]. In the case of scoparone, the presence of its lactonic ring can inhibit the levels of the NF- κ B-DNA complex. It can also inhibit dose-dependent phosphorylation of I κ B α and nuclear translocation of NF- κ B1 [47]. Finally, the low activity of phanurane can be attributed to its lactonic ring, which partially inhibits one of the stages of the cytoplasmic signalling pathway of NF- κ B and the nucleus, namely, the phosphorylation of I κ B α in the cytoplasm [48]. The damsine and scoparone compounds had a better inhibitory activity on NF- κ B than the JSH-23 control (IC₅₀ = 7.1 μ M) in all tumour cell lines, except in the Caco-2 cell line (► Fig. 2).

Regarding the mechanism of inhibitory action over HIF-1 α by the compounds isolated from the dichloromethane/methanol ex-

tract of *S. graveolens*, we could indicate, based on the bioinformatic experiment conducted by Dawood et al. [50], that sesquiterpene lactones inhibiting NF- κ B also possess the ability to inhibit HDAC (histone deacetylase). The latter leads to the inhibition of HIF- α in different tumour cell lines. This phenomenon is suggested as a mechanism of collateral sensitivity [49]. In the case of scoparone, like other coumarins, it would cause degradation of HIF-1 α , weakening glycolysis and all activities related to apoptosis in tumour cells [50]. Finally, regarding phanurane, there is no clear mechanism of its activity on HIF-1 α . There is a report by Yim et al. [51] which mentions that spironolactone (compound structurally similar to phanurane) improved the hypoxic response and increased the expressions of HIF-1 α and Ets-1 in the kidneys of newborn rats. However, they indicate that to clarify the hypoxic changes, it is necessary to investigate what types of signal cascades exist between RAAS (renin-angiotensin-aldosterone system) and renal hypoxia. These results corroborate our results, since the phanurane compound did not inhibit the activity of HIF-1 α in the tumour cell lines analysed. On the contrary, we can indicate that phanurane increased its activity. None of the compounds showed a better inhibitory activity over HIF-1 α than the 2-MeOE2 control (IC₅₀ = 0.5 μ M) in all tumour cell lines (► Fig. 3).

It should be noted that in the work of Echiburú-Chau et al. [6] they mentioned that the majority compound [4-hydroxy-3-(3-methyl-2-butenyl) acetophenone] of the alcoholic extract presented less cytotoxic activity on different tumour cellular lines than the complete extract. However, in our case, the major compounds (phanurane, damsine, and scoparone) of the dichloromethane/methanol extract showed greater cytotoxic activity over different tumour cellular lines than the complete extract (► Table 3).

Both HIF-1 α and NF- κ B are involved in cancer progression and have been implicated in the tumour responses to hypoxia [52]. Moreover, positive correlations between HIF-1 α and NF- κ B have been shown in various cancer cells, including lung cancer cells, colorectal cancer cells, osteosarcoma, and gastric cancer cells [53, 54]. Our results corroborate that both HIF-1 α and NF- κ B are involved in the progression of cancer and have been implicated in tumour responses to hypoxia. In addition, we have shown positive correlations between HIF-1 α and NF- κ B in cancer cell lines U-373 MG, A549, Hep G2, and Caco-2. Likewise, it is the first time that the inhibitory activity over HIF-1 α is reported by means of the phanurane, damsine, and scoparone compounds, in addition to reporting for the first time the inhibitory activity of phanurane in NF- κ B. Finally, we indicate, based on our results, that the inhibition of NF- κ B could regulate both HIF-1 α signalling and the progression of the epithelial-mesenchymal transition induced by hypoxia.

In conclusion, considering the multiple roles of HIF-1 α in tumour progression and metastasis, phanurane, damsine, and scoparone compounds must be considered prototype molecules for the development of novel drugs aimed at inhibiting this pathway, due to their high cytotoxic capacity over different cancer cell lines. Since the HIF-1 α regulatory pathway is a highly complex network involving several signalling cascades and overlapping mechanisms, each one of them could serve as a promising target or step to intervene tumours in the future.

Materials and Methods

Cell lines, chemicals, and biochemicals

Four human cancer cell lines were used in this study: U-373 MG, A549, Hep G2, and Caco-2, and the non-tumorigenic PBMCs cell line. All cell lines were obtained from ATCC. Cells were cultured in specific media according to ATCC recommendations. PBMCs were obtained from whole blood by density gradient centrifugation using Lymphoprep (StemCell Technologies) according to the manufacturer's instructions. In both cases, the incubation condition was established at 37 °C in hypoxic conditions (1 % O₂), thus mimicking the *in vivo* tumour microenvironment.

We used first grade organic solvents for isolating the compounds. TLC was performed using Merck Silica gel 60-F₂₅₄ plates. Chromatograms thus obtained were visualised by UV absorbance (254 nm) and through heating a plate stained with phosphomolybdic acid. Manual flash chromatography was performed with flash grade Silica gel 60 (20–45 and 40–63 μM; Merck).

DMEM, RPMI, FBS, and PBS were obtained from Sigma-Aldrich. L-Glutamine was obtained from Applichem. Penicillin and streptomycin were purchased from PAA. Test compounds were dissolved in DMSO (Merck) at a 10 mM concentration, while the extracts and fractions were dissolved at 20 mg/mL in DMSO.

Plant material

A sample of *S. graveolens* was collected from the Pongo community (Murillo province, La Paz, Bolivia) in August 2018 at an altitude of 3800 m. Botanical identification was confirmed by the National Herbarium of Bolivia (No. 13898).

Extraction and isolation

S. graveolens leaves (2 kg) were extracted by repeated maceration with 2.5 L of different solvents, increasing the polarity: *n*-heptane, dichloromethane/methanol (1:1), and water. As a result, three extracts of 120, 95, and 375 g, respectively, were obtained.

Each extract was evaluated for its cytotoxic effects and its influence on the inhibition of HIF-1α as well as on its modulator NF-κB. Only the *n*-heptanic extract showed significant cytotoxicity on the noncancerous cell line (► **Table 1**), whereas the dichloromethane/methanol extract showed a greater inhibition of NF-κB and HIF-1α, being more active than the aqueous extract (► **Tables 2** and ► **3**). Therefore, the chemical constituents of the dichloromethane/methanol extract were investigated to identify specific compounds with cytotoxic potential.

The dichloromethane/methanol extract was analysed through bioassay-guided Silica gel (40–63 μM) column chromatography (2 × 50 cm) using a step gradient of *n*-heptane, dichloromethane and ethyl acetate (50/50/0 to 50/0/50) to produce 15 fractions (I–XV). Among them, III and IV were the fractions that showed the highest activity (inhibition of HIF-1α as well as of its modulator NF-κB).

As a result, fractions III and IV were combined and a second bioassay-guided Silica gel (40–63 μM) column chromatography (2 × 50 cm) was performed using step gradient *n*-heptane and dichloromethane (50/0 to 0/50). Nine fractions were obtained (1–9). Nine fractions showed inhibition of HIF-1α as well as of its modulator NF-κB, but fractions 1, 5, and 7 were the most active.

Fraction 1 was separated in a column (2 × 30 cm) of Silica gel (40–63 μM) with *n*-heptane/ethyl acetate, 80:20, from which six fractions were obtained (1a–1f). Fraction 1b was the most active and it was further chromatographed in a column (2 × 30 cm) of Silica gel (20–45 μM) (*n*-heptane/ethyl acetate, 60:40), obtaining compound **1** (14 mg).

Next, fraction 5 was chromatographed on a column (2 × 30 cm) of Silica gel (40–63 μM) with *n*-heptane/ethyl acetate, 60:40, to produce nine fractions (5a–5i), with the 5f fraction being the most active one. Fraction 5f was chromatographed in a column (2 × 30 cm) of Silica gel (20–45 μM) (*n*-heptane/ethyl acetate, 50:50) to isolate compound **2** (11 mg).

Finally, fraction 7 was fractionated by a column (2 × 30 cm) of Silica gel (40–63 μM) with *n*-heptane/ethyl acetate, 20:80, providing ten fractions (7a–7j), from which fraction 7i was chromatographed in a column (2 × 30 cm) of Silica gel (20–45 μM) (*n*-heptane/ethyl acetate, 40:60) to obtain compound **3** (5 mg).

NMR/MS analysis

NMR experiments were performed on a Bruker BioSpin GmbH spectrometer operating at 700 MHz (¹H) or 175 MHz (¹³C). Deuterated solvents were methanol-d₄ and chloroform-d₁. Spectra were calibrated by assignment of the residual solvent peak to δ_H 3.31 ppm and δ_C 49.0 ppm for methanol-d₄, and δ_H 7.2 ppm and δ_C 77.0 ppm for chloroform-d₁. Complete assignment of protons and carbons was done by analysing the correlated ¹H-¹H COSY, ¹H-¹³C HSQC, and ¹H-¹³C HMBC spectra. HREIMS analyses were performed using a mass spectrometer with QTOF hybrid analyser model Q-Star Pulsar I from the commercial house Applied Biosystems. MS samples were prepared in MeOH + formic acid 0.1 % and analysed by the electrospray ionisation technique in the positive ion detection mode.

Cytotoxic assay

Cell viability was determined in a panel of four human cancer cell lines (U-373 MG, A549, Hep G2, Caco-2) and one noncancerous cell line (PBMCs) by MTT (≥ 97.5 %, Sigma-Aldrich) and LDH (Cytotoxicity Detection Kit; Sigma-Aldrich) assays. Cells were seeded in 96-well plates at a density of 2 × 10⁴ cells/well, and then they were left for 24 h at 37 °C in a humidified atmosphere with 5 % CO₂. After that, cells were treated with various concentrations (100, 50, 25, 12.5, 6.25, 3.125, 1.563, 0.781, 0.391, and 0.95 μM) of the isolated compounds in hypoxic conditions (1 % O₂).

MTT cytotoxicity assay: Following a 72-h incubation, a volume of 20 μL PBS containing 4 mg/mL MTT was added to each well. After this, plates were incubated for 4 h, before they were centrifuged at 1500 rpm at 4 °C for 10 min, followed by the removal of the supernatant. Then, DMSO (150 μL) was added to each well for colouration, and the plates were subsequently shaken vigorously to ensure complete solubilisation for 10 min at room temperature. The light absorption (OD, optical densities) was recorded on a spectrophotometric ELISA plate reader (SpectraMax i3, Molecular Devices) at a wavelength of 590 nm.

LDH cytotoxicity assay: After 72 h of treatment with the compounds, 100 μL of culture supernatants were collected and incubated in the reaction mixture from the LDH kit (Innoprot Company). After 30 min, the reaction was stopped by adding HCl 1 N, and

the absorbance at a wavelength of 490 nm was measured using a spectrophotometric ELISA plate reader (SpectraMax i3; Molecular Devices).

Nuclear factor kappa-light-chain-enhancer of activated B cells inhibition assay

Cells were transfected using a lipofectamine plus transfection reagent (Thermo Fisher Scientific) with 0.3 μg of the NF- κB -promoted luciferase reporter gene plasmid (pGL2-NF- κB -Luc) (Promega), and 0.03 μg of the Renilla luciferase reporter plasmid (pTK-Renilla) (transfection normalisation vector; Promega). After 1 day, the cells were incubated with TNF- α (5 ng/mL) in the absence or presence of the isolated compounds at different concentrations (100, 50, 25, 12.5, 6.25, 3.125, 1.563, 0.781, 0.391, and 0.95 μM) for 72 h of treatment in hypoxic conditions (1 % O_2). JSH-23 ($\geq 98\%$; Sigma-Aldrich) was used as a positive control at a concentration of 7.1 μM . Next, the cells were lysed in 25 mM Tris-phosphate, pH 7.8, containing 8 mM MgCl_2 , 1 mM dithiothreitol (DTT), 1 % Triton X-100, and 7 % glycerol. Luciferase activity was measured by a Dual-Luciferase Reporter Assay Kit (Promega) according to the manufacturer's instructions.

Hypoxia-inducible factor 1-alpha inhibition assay

Cells were stably transfected with plasmid Epo-Luc plasmid. EPO-hypoxia response element (HRE)-luciferase reporter plasmid contains three copies of the HRE consensus sequence from the promoter of the erythropoietin gene in the pGL3 vector. Cells (1×10^4) were seeded the day before the assay. The next day, the cells were stimulated with the test compounds at different concentrations (100, 50, 25, 12.5, 6.25, 3.125, 1.563, 0.781, 0.391, and 0.95 μM). 2-MeOE2 ($\geq 99\%$; Sigma-Aldrich) was used as a positive control at a concentration of 0.5 μM . After 72 h of stimulation in hypoxic conditions (1 % O_2), the cells were lysed in 25 mM Tris-phosphate pH 7.8, 8 mM MgCl_2 , 1 mM DTT, 1 % Triton X-100, and 7 % glycerol during 15 min at RT in a horizontal shaker. Luciferase activity was measured using a GloMax 96 microplate luminometer (Promega) following the instructions of the luciferase assay kit (Promega). The RLU was calculated and the results are expressed as percentage of inhibition induction/inhibition of EPO-luc activity. Experiments for each concentration of the test items were done in triplicate wells.

Statistical analysis

Statistical significance of differences was calculated employing GraphPad Prism software, version 8.2.0 (GraphPad Software Inc.) using one-way ANOVA followed by Tukey's post hoc test for multiple comparisons. Results were considered different when $p < 0.0001$. IC_{50} values were determined by nonlinear regression using GraphPad Prism, version 8.2.0. All the experiments were performed in triplicate.

Phanurane (**1**): white amorphous powder; m.p. = 149°C; $^1\text{H-NMR}$ (700 MHz, CDCl_3) δ_{H} = 6.14 (1H, dd, J = 9.8, 2.7 Hz, H-6), 6.09 (1H, dd, J = 9.7, 2.0 Hz, H-7), 5.69 (1H, s, H-4), 2.58 (1H, m, H-21), 2.55 (1H, m, H-2), 2.50 (1H, m, H-21'), 2.42 (1H, m, H-2'), 2.37 (1H, ddd, J = 13.0, 9.1, 6.1 Hz, H-20), 2.31 (1H, m, H-16), 2.30 (1H, m, H-8), 2.02 (1H, ddd, J = 13.1, 5.4, 2.1 Hz, H-1), 1.92 (1H, ddd, J = 12.8, 9.2, 7.3 Hz, H-20'), 1.89 (1H, m, H-15), 1.87 (1H, m, H-16'), 1.68 (1H, m, H-1'), 1.66 (1H, m, H-11), 1.63 (1H, m, H-12), 1.57

(1H, m, H-15'), 1.47 (1H, qd, J = 12.7, 3.6 Hz, H-11), 1.37 (1H, m, C-12'), 1.36 (1H, m, H-14), 1.20 (1H, m, J = 13.2, 7.5, 2.5 Hz, H-9), 1.13 (3H, s, H-19), 1.04 (3H, s, H-18); $^{13}\text{C-NMR}$ (176 MHz, CDCl_3) δ_{C} = 199.57 (C-3), 176.74 (C-22), 163.20 (C-5), 139.56 (C-7), 128.50 (C-6), 124.14 (C-4), 95.52 (C-17), 50.58 (C-9), 47.17 (C-14), 46.59 (C-13), 37.95 (C-8), 36.19 (C-6), 35.63 (C-16), 34.09 (C-1), 34.05 (C-2), 31.78 (C-12), 31.33 (C-20), 29.41 (C-21), 22.62 (C-15), 20.25 (C-11), 16.49 (C-19), 14.58 (C-18); HRESIMS m/z 341.2117 [$\text{M} + \text{H}^+$] + 363.1943 [$\text{M} + \text{Na}^+$] + 703.3992 [$2\text{M} + \text{Na}^+$] (calcd. for $\text{C}_{22}\text{H}_{28}\text{O}_3$). Data compared to the reference Preisig et al. [55].

Damsine (**2**): white crystalline solid; m.p. = 107°C; $^1\text{H-NMR}$ (700 MHz, MeOD) δ_{H} = 6.18 (1H, d, J = 3.2 Hz, H-14), 5.64 (1H, d, J = 2.8 Hz, H-14'), 4.59 (1H, d, J = 8.7 Hz, H-6), 3.40 (1H, dddd, J = 11.7, 6.1, 4.6, 3.1 Hz, H-7), 2.40 (2H, H-3, H-3'), 2.19 (1H, m, H-10), 2.18 (1H, m, H-1), 2.03 (2H, m, H-8, H-8'), 1.90 (1H, dddd, J = 14.8, 7.8, 4.6, 1.8 Hz, H-2), 1.84 (1H, ddd, J = 11.8, 5.5, 1.4 Hz, H-2'), 1.79 (2H, m, H-9, H-9'), 1.08 (3H, d, J = 7.2 Hz, H-15), 1.03 (3H, s, H-11); $^{13}\text{C-NMR}$ (176 MHz, MeOD) δ_{C} = 222.13 (C-4), 172.65 (C-13), 141.65 (C-12), 121.58 (C-14), 83.68 (C-6), 56.22 (C-5), 47.09 (C-1), 45.57 (C-7), 36.83 (C-3), 35.76 (C-10), 34.41 (C-9), 26–61 (C-2), 24.99 (C-8), 16.22 (C-15), 14.23 (C-11); m/z 249.1496 [$\text{M} + \text{H}^+$] + 271.1316 [$2\text{M} + \text{Na}^+$] (calcd. for $\text{C}_{15}\text{H}_{20}\text{O}_3$). Data compared to the reference Li et al. [56].

Scoparone (**3**): amber crystalline solid; m.p. = 144°C; $^1\text{H-NMR}$ (700 MHz, CDCl_3) δ_{H} = 7.62 (1H, d, J = 9.4 Hz, H-4), 6.85 (d, J = 5.4 Hz, H-5 and H-8), 6.29 (1H, d, J = 9.4 Hz, H-3), 3.95 (3H, s, 6-OMe), 3.92 (3H, s, 7-OMe); $^{13}\text{C-NMR}$ (176 MHz, CDCl_3) δ_{C} = 161.57 (C-2), 152.99 (C-7), 150.19 (C-9), 146.49 (C-6), 143.44 (C-4), 113.72 (C-3), 111.58 (C-10), 108.09 (C-5), 100.17 (C-8), 56.53 (OMe-6), 56.50 (OMe-7); m/z 207.0598 [$\text{M} + \text{H}^+$] + 229.0480 [$\text{M} + \text{Na}^+$] (calcd. for $\text{C}_{11}\text{H}_{10}\text{O}_4$). Data compared to that of Ma et al. [57].

Supporting Information

NMR and MS data of the compounds are available as Supporting Information.

Acknowledgments

This work was supported by the National Herbarium of Bolivia, the Fundación de la Universidad Autónoma de Madrid (FUAM).

Conflict of Interest

The authors declare no conflict of interest.

References

- [1] De Lucca DM, Zalles AJ. Utasan Utjir Qollanaka. Medicinas junto a nuestra casa, 1^{er} edition. La Paz: Agencia Española de Cooperación Internacional 2006; 72
- [2] Araya-Presa J, Squeo FA, Barrientos L, Belmonte E, Mamani M, Arancio G. Manual de plantas y canciones Aymara, 1^{er} edition. Arica: Universidad de La Serena; 2003: 4–5

- [3] Oblitas EP. Plantas medicinales de Bolivia, 1^{er} edition. Cochabamba: Los amigos del libro; 1993: 143–144
- [4] De Lucca DM, Zalles AJ. Flora medicinal boliviana, 1^{er} edition. Cochabamba: Los amigos del libro 1992; 361
- [5] Camaqui Mendoza A. Plantas medicinales: La experiencia de Tinguipaya, 1^{er} edition. La Paz: Gente Común; 2007: 69–70
- [6] Echiburú-Chau C, Alfaro-Lira S, Brown N, Salas CO, Cuellar M, Santander J, Ogalde JP, Rothhammer F. The selective cytotoxicity elicited by phytochemical extract from *Senecio graveolens* (Asteraceae) on breast cancer cells is enhanced by hypoxia. *Int J Oncol* 2014; 44: 1357–1364
- [7] Brahimi-Horn MC, Chiche J, Pouyssegur J. Hypoxia and cancer. *J Mol Med* 2007; 85: 1301–1307
- [8] Harris AL. Hypoxia—a key regulatory factor in tumour growth. *Nat Rev Cancer* 2002; 2: 38–47
- [9] Dewhirst MW, Cao Y, Moeller B. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. *Nat Rev Cancer* 2008; 8: 425–437
- [10] Quintero M, Mackenzie N, Brennan PA. Hypoxia-inducible factor 1 (HIF-1) in cancer. *Eur J Surg Oncol* 2004; 30: 465–468
- [11] Semenza GL. Hypoxia-inducible factors: Mediators of cancer progression and targets for cancer therapy. *Trends Pharmacol Sci* 2012; 33: 207–214
- [12] Shanmugam MK, Lee JH, Chai EZ, Kanchi MM, Kar S, Arfuso F, Dharmarajan A, Kumar AP, Ramar PS, Looi CY, Mustafa MR, Tergaonkar V, Bishayee A, Ahn KS, Sethi G. Cancer prevention and therapy through the modulation of transcription factors by bioactive natural compounds. *Semin Cancer Biol* 2016; 40–41: 35–47
- [13] Manolescu B, Oprea E, Busu C, Cercasov C. Natural compounds and the hypoxia-inducible factor (HIF) signalling pathway. *Biochimie* 2009; 91: 1347–158
- [14] Kim SL, Park YR, Lee ST, Kim SW. Parthenolide suppresses hypoxia-inducible factor-1 α signalling and hypoxia induced epithelial-mesenchymal transition in colorectal cancer. *Int J Oncol* 2017; 51: 1809–1820
- [15] Welsh SJ, Powis G. Hypoxia inducible factor as a cancer drug target. *Curr Cancer Drug Targets* 2003; 3: 391–405
- [16] van Uden P, Kenneth NS, Rocha S. Regulation of hypoxia-inducible factor-1 α by NF- κ B. *Biochem J* 2008; 412: 477–484
- [17] Balamurugan K. HIF-1 at the crossroads of hypoxia, inflammation, and cancer. *Int J Cancer* 2016; 138: 1058–1066
- [18] Belaiba RS, Bonello S, Zahringer C, Schmidt S, Hess J, Kietzmann T, Grolach A. Hypoxia up-regulates hypoxia-inducible factor-1 α transcription by involving phosphatidylinositol 3-kinase and nuclear factor κ B in pulmonary artery smooth muscle cells. *Mol Biol Cell* 2007; 18: 4691–4697
- [19] Bonello S, Zahringer C, Belaiba RS, Djordjevic T, Hess J, Michiels C, Kietzmann T, Grolach A. Reactive oxygen species activate the HIF-1 α promoter via a functional NF- κ B site. *Arterioscler Thromb Vasc Biol* 2007; 27: 755–761
- [20] Parra C, Soto E, León G, Salas CO, Heinrich M, Echiburú-Chau C. Nutritional composition, antioxidant activity and isolation of scopoletin from *Senecio nutans*: Support of ancestral and new uses. *Nat Prod Res* 2018; 32: 719–722
- [21] Dupré S, Grenz M, Jakupovic J, Bohlmann F, Niemeyer HM. Eremophilane, germacrane and shikimic acid derivatives from Chilean *Senecio* species. *Phytochemistry* 1991; 30: 1211–1220
- [22] Loyola LA, Pedreros S, Morales G. *p*-Hydroxyacetophenone derivatives from *Senecio graveolens*. *Phytochemistry* 1985; 24: 1600–1602
- [23] Saeed M, Jacob S, Sandjo LP, Sugimoto Y, Khalid HE, Opatz T, Thines E, Efferth T. Cytotoxicity of the Sesquiterpene Lactones Neoambrosin and Damsin from *Ambrosia maritima* Against Multidrug-Resistant Cancer Cells. *Front Pharmacol* 2015; 6: 267
- [24] Sotillo WS, Villagomez R, Smiljanic S, Huang X, Malakpour A, Kempengren S, Rodrigo G, Almanza G, Sterner O, Oredsson S. Anti-cancer stem cell activity of a sesquiterpene lactone isolated from *Ambrosia arborescens* and of a synthetic derivative. *PLoS One* 2017; 12: e0184304
- [25] Kim JK, Kim JY, Kim HJ, Park KG, Harris RA, Cho WJ, Lee JT, Lee IK. Scoparone exerts anti-tumour activity against DU145 prostate cancer cells via inhibition of STAT3 activity. *PLoS One* 2013; 8: e80391
- [26] Shin HM, Kim MH, Kim BH, Jung SH, Kim YS, Park HJ, Hong JT, Min KR, Kim Y. Inhibitory action of novel aromatic diamine compound on lipopolysaccharide-induced nuclear translocation of NF- κ B without affecting I κ B degradation. *FEBS Lett* 2004; 571: 50–54
- [27] Villagomez R, Rodrigo GC, Collado IG, Calzado MA, Muñoz E, Akesson B, Sterner O, Almanza GR, Duan RD. Multiple anticancer effects of damsine and coronopilin isolated from *Ambrosia arborescens* on cell cultures. *Anticancer Res* 2013; 33: 3799–3805
- [28] Jang SI, Kim YJ, Kim HJ, Lee JC, Kim HY, Kim YC, Yun YG, Yu HH, You YO. Scoparone inhibits PMA-induced IL-8 and MCP-1 production through suppression of NF- κ B activation in U937 cells. *Life Sci* 2006; 78: 2937–2943
- [29] Lakhani NJ, Sarkar MA, Venitz J, Figg WD. 2-Methoxyestradiol, a promising anticancer agent. *ACCP* 2003; 23: 165–172
- [30] De Feo V, Urrunaga Soria E, Urrunaga Soria R, Senatore F. Chemical composition of essential oils of *Senecio nutans* Sch.-Bip. (Asteraceae). *Flavour Fragr J* 2003; 18: 234–236
- [31] Galvez CE, Jimenez CM, Gomez ALA, Lizarraga EF, Sampietro DA. Chemical composition and antifungal activity of essential oils from *Senecio nutans*, *Senecio viridis*, *Tagetes terniflora* and *Aloysia gratissima* against toxigenic *Aspergillus* and *Fusarium* species. *Nat Prod Res* 2018; 1–4. doi:10.1080/14786419.2018.1511555
- [32] Pérez C, Agnese AM, Cabrera JL. The essential oil of *Senecio graveolens* (Compositae): Chemical composition and antimicrobial activity tests. *J Ethnopharmacol* 1999; 66: 91–96
- [33] Juarez Belaunde A, Guerriero Sandoval J, De Martino L, Senatore F, De Feo V. Chemical Composition and Antibacterial Activity of *Senecio nutans* Essential Oil. *Jeobp* 2007; 10: 332–338
- [34] Paredes A, Palacios J, Quispe C, Nwokocho CR, Morales G, Kuzmicic J, Cifuentes F. Hydroalcoholic extract and pure compounds from *Senecio nutans* Sch. Bip (Compositae) induce vasodilation in rat aorta through endothelium-dependent and independent mechanisms. *J Ethnopharmacol* 2016; 192: 99–107
- [35] Santander J, Otto C, Lowry D, Cuellar M, Mellado M, Salas C, Rothhammer F, Echiburú-Chau C. Specific Gram-Positive Antibacterial Activity of 4-hydroxy-3-(3-methyl-2-butenyl) Acetophenone Isolated from *Senecio graveolens*. *Br Microbiol Res J* 2015; 5: 94–106
- [36] Soberón JR, Lizarraga EF, Sgariglia MA, Carrasco Juárez MB, Sampietro DA, Ben Altabef A, Catalán CA, Vattuone MA. Antifungal activity of 4-hydroxy-3-(3-methyl-2-butenyl) acetophenone against *Candida albicans*: evidence for the antifungal mode of action. *Antonie Van Leeuwenhoek* 2015; 108: 1047–1057
- [37] Cifuentes F, Paredes A, Palacios J, Muñoz F, Carvajal L, Nwokocho CR, Morales G. Hypotensive and antihypertensive effects of a hydroalcoholic extract from *Senecio nutans* Sch. Bip. (Compositae) in mice: Chronotropic and negative inotropic effect, a nifedipine-like action. *J Ethnopharmacol* 2016; 179: 367–374
- [38] Ko S, Lee MK, Shin D, Park H. Structure-based virtual screening approach to the discovery of novel inhibitors of factor-inhibiting HIF-1: Identification of new chelating groups for the active-site ferrous ion. *Bioorg Med Chem* 2009; 17: 7769–7774
- [39] Han HW, Zheng CS, Chu SJ, Sun WX, Han LJ, Yang RW, Qi JL, Lu GH, Wang XM, Yang YH. The evaluation of potent antitumor activities of shikonin coumarin-carboxylic acid, PMMB232 through HIF-1 α -mediated apoptosis. *Biomed Pharmacother* 2018; 97: 656–666

- [40] Manolescu B, Oprea E, Busu C, Cercasov C. Natural compounds and the hypoxia-inducible factor (HIF) signalling pathway. *Biochimie* 2009; 91: 1347–1358
- [41] Xia M, Huang R, Sun Y, Semenza GL, Aldred SF, Witt KL, Inglese J, Tice RR, Austin CP. Identification of chemical compounds that induce HIF-1 α activity. *Toxicol Sci* 2009; 112: 153–163
- [42] Diaz-Gonzalez JA, Russell J, Rouzaut A, Gil-Bazo I, Montuenga L. Targeting hypoxia and angiogenesis through HIF-1 α inhibition. *Cancer Biol Ther* 2005; 4: 1055–1062
- [43] Li Y, Lin Z, Chen B, Chen S, Jiang Z, Zhou T, Hou Z, Wang Y. Ezrin/NF- κ B activation regulates epithelial-mesenchymal transition induced by EGF and promotes metastasis of colorectal cancer. *Biomed Pharmacother* 2017; 92: 140–148
- [44] Scherbakov AM, Lobanova YS, Shatskaya VA, Krasil'nikov MA. The breast cancer cells response to chronic hypoxia involves the opposite regulation of NF- κ B and estrogen receptor signalling. *Steroids* 2009; 74: 535–542
- [45] Picman AK, Rodriguez E, Towers GH. Formation of adducts of parthenin and related sesquiterpene lactones with cysteine and glutathione. *Chem Biol Interact* 1979; 28: 83–89
- [46] Denk A, Goebeler M, Schmid S, Berberich I, Ritz O, Lindemann D, Ludwig S, Wirth T. Activation of NF- κ B via the I κ B kinase complex is both essential and sufficient for proinflammatory gene expression in primary endothelial cells. *J Biol Chem* 2001; 276: 28451–28458
- [47] Haddad JJ, Safieh-Garabedian B, Saade NE, Land SC. The biphasic immunoregulation of pyrimidylpiperazine (Y-40138) is IL-10 sensitive and requires NF- κ B targeting in the alveolar epithelium. *Br J Pharmacol* 2001; 133: 49–60
- [48] Sønder SU, Woetmann A, Odum N, Bendtzen K. Spironolactone induces apoptosis and inhibits NF- κ B independent of the mineralocorticoid receptor. *Apoptosis* 2006; 11: 2159–2165
- [49] Han HW, Zheng CS, Chu SJ, Sun WX, Han LJ, Yang RW, Qi JL, Lu GH, Wang XM, Yang YH. The evaluation of potent antitumor activities of shikonin coumarin-carboxylic acid, PMMB232 through HIF-1 α -mediated apoptosis. *Biomed Pharmacother* 2018; 97: 656–666
- [50] Dawood M, Ooko E, Efferth T. Collateral Sensitivity of Parthenolide via NF- κ B and HIF- α Inhibition and Epigenetic Changes in Drug-Resistant Cancer Cell Lines. *Front Pharmacol* 2019; 10: 542
- [51] Yim HE, Kim JH, Yoo KH, Bae IS, Jang GY, Hong YS, Lee JW. Spironolactone, but not enalapril, potentiates hypoxia-inducible factor-1 α and Ets-1 expression in newborn rat kidney. *J Physiol Pharmacol* 2010; 61: 73–81
- [52] Patel H, Zaghoul N, Lin K, Liu SF, Miller EJ, Ahmed M. Hypoxia-induced activation of specific members of the NF- κ B family and its relevance to pulmonary vascular remodelling. *Int J Biochem Cell Biol* 2017; 92: 141–147
- [53] Ghasemi F, Sarabi PZ, Athari SS, Esmaeilzadeh A. Therapeutics strategies against cancer stem cell in breast cancer. *Int J Biochem Cell Biol* 2019; 109: 76–81
- [54] Yan R, Sun L, Zhang H. Metabolic reprogramming and tumour immunity under hypoxic microenvironment. *Curr Opin Physiol* 2019; 7: 53–59
- [55] Preisig CL, Laakso JA, Mocek UM, Wang PT, Baez J, Byng G. Biotransformations of the cardiovascular drugs mexrenone and canrenone. *J Nat Prod* 2003; 66: 350–356
- [56] Li C, Tu S, Wen S, Li S, Chang J, Shao F, Lei X. Total synthesis of the G2/M DNA damage checkpoint inhibitor psilostachyin C. *J Org Chem* 2011; 76: 3566–3570
- [57] Ma CH, Ke W, Sun ZL, Peng JY, Li ZX, Zhou X, Fan GR, Huang CG. Large-Scale Isolation and Purification of Scoparone from *Herba artemisiae scopariae* by High-Speed Counter-Current Chromatography. *Chromatographia* 2006; 64: 83–87